Together, we can help shape what’s next. Reach out to start the conversation.

General Contact
Message Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
General Contact
Message Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Exploring a New Path for Patients with CKD

At Pathalys, we are committed to supporting the unique needs of patients through the development of therapeutics that may improve the management of chronic kidney disease (CKD).

Patients are already managing the demands of CKD – SHPT adds complexity.

People with CKD on hemodialysis manage a life organized around their condition. Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease in patients receiving dialysis, developing as the body struggles to maintain healthy calcium, phosphorus and parathyroid hormone levels when kidney function is lost.

Elderly man sitting in a chair undergoing dialysis treatment connected to a dialysis machine by tubes in a medical setting.

We aim to help address the complexities of uncontrolled SHPT.

Pathalys is developing a new calcimimetic that may give clinicians a new tool to help manage SHPT.

Close-up of a patient holding blood-filled dialysis tubing.
Older man and young child smiling at each other in warm sunlight.

Dialysis patients deserve more options.

At Pathalys, we are drawn to the challenges of CKD, not because they are easy, but because every patient deserves access to innovation and opportunity.

Interested in joining a small, but mighty team?